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High-resolution Manometry Determinants of
Refractoriness of Reflux Symptoms to Proton
Pump Inhibitor Therapy
Mentore Ribolsi,1* Edoardo Savarino,2 Benjamin Rogers,3 Arvind Rengarajan,3 Marco Della Coletta,2 Matteo Ghisa,2 Michele
Cicala,1 and C Prakash Gyawali3
1
Unit of Gastroenterology, Campus Bio Medico University, Rome, Italy; 2Division of Gastroenterology, Department of Surgical, Oncological
and Gastroenterological Sciences, University of Padua, Padua, Italy; and 3Division of Gastroenterology, Department of Medicine, Washington
University School of Medicine, St. Louis, MO, USA

Background/Aims
Impaired esophageal motility and disrupted esophagogastric junction (EGJ) on high-resolution manometry (HRM) have been
associated with increased reflux severity in gastroesophageal reflux disease (GERD) patients. However, there are limited data evaluating
HRM parameters in proton pump inhibitors (PPI) non-responders.
Methods
Clinical and endoscopic data, HRM and multichannel intraluminal impedance-pH studies performed of PPI therapy in patients with
typical GERD symptoms were reviewed from 3 international centers. Frequency of GERD symptoms was assessed on and off PPI
therapy in both non-responders (< 50% symptom improvement on PPI therapy) and responders. Rome IV definitions identified
non-erosive reflux disease, reflux hypersensitivity, and functional heartburn. Univariate and multivariate analyses were performed to
determine predictors of non-response.
Results
Of 204 patients, 105 were PPI non-responders and 99 were responders. Non-responders showed higher EGJ contractile integral
values, and a lower frequency of type II and III EGJ morphology (P ≤ 0.03 for each comparison). Esophageal body diagnoses on HRM
(fragmented peristalsis, ineffective esophageal motility, or absent peristalsis) did not predict non-response. On multivariate analysis,
non-pathological acid exposure time (OR, 2.5; 95% CI, 1.2-5.0; P < 0.001), normal mean nocturnal baseline impedance values (OR,
2.7-2.4; 95% CI, 1.0-6.1; P < 0.05), normal EGJ contractile integral values (OR, 3; 95% CI, 1.3-7.4; P = 0.012), and presence of type I
EGJ morphology (OR, 1.9; 95% CI, 1.0-3.4; P = 0.044) were associated with an unfavorable response to PPIs.
Conclusions
Intact EGJ metrics on HRM complement normal reflux burden in predicting non-response to PPI therapy. HRM has value in the
evaluation of PPI non-responders.
(J Neurogastroenterol Motil 2020;26:447-454)
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Introduction
Gastroesophageal reflux disease (GERD), defined by the
presence of esophageal and extra-esophageal symptoms due to
pathological reflux of gastric content, represents one of the most
common gastrointestinal disorders, with an increasing worldwide
prevalence.1-3 However, as many as 40% of patients with GERD
symptoms report an unsatisfactory response to acid suppression
with proton pump inhibitor (PPI) therapy,4,5 and evaluating pathophysiology and mechanisms of symptom generation are critical to
further investigation of these patients.
With the development of high-resolution manometry (HRM),
more specific evaluation of esophageal motor function has expanded
our knowledge of inter-relationships with GERD.6,7 HRM also
allows precise characterization of esophagogastric junction (EGJ)
morphology and identification of hiatus hernia.8 The esophagogastric junction contractile integral (EGJ-CI) is a HRM tool that
assesses EGJ barrier function,9 and low EGJ-CI is associated with
abnormal total and supine acid burden.10 Abnormal EGJ morphology is associated with a higher probability of positive multichannel
intraluminal impedance pH (MII-pH) monitoring compared to
normal EGJ morphology, and both EGJ morphology and EGJ-CI
independently predict esophageal reflux burden.11
While EGJ disruption or dysfunction is a primary pathophysiologic factor in determining reflux occurrence, esophageal body
motor function influences duration of contact of the refluxate with
the esophageal mucosa. Consequently, impaired esophageal peristalsis may account for delayed bolus transit and reduced esophageal
reflux clearance in patients with GERD.12 Early studies using
conventional manometry demonstrated higher prevalence of low
amplitude (< 30 mmHg) or non-transmitted esophageal body
contractions in GERD patients, and these motility abnormalities
increase in parallel with the severity of GERD.13,14 For instance, the
presence of large breaks in esophageal peristaltic integrity on HRM
is associated with significantly prolonged supine reflux clearance,
higher acid exposure time (AET), and erosive esophagitis.15 Large
breaks are often identified in the context of suspected GERD-related chronic cough,16,17 the presence of which can be associated with
suboptimal benefit from antireflux therapy.16 Finally, failed swallows,
which represent panesophageal breaks in peristaltic integrity, predict
abnormal AET better than ineffective swallows without long breaks
in peristaltic integrity.8
Despite these advances in assessment of esophageal motor
function, no studies have evaluated HRM parameters in PPI non448

responders. The present investigation is a multicenter, observational
study aimed at evaluating and comparing HRM parameters between PPI responders and non-responders in patients with GERD
symptoms.

Materials and Methods
Patients
Adult patients (age > 18 years) with suspected GERD evaluated with HRM and 24-hour MII-pH monitoring at 3 centers (2
in Europe and 1 in the United States) over a 2-year period (20172019) for symptoms unresponsive to acid suppressive therapy
or prior to anti-reflux surgery were eligible for inclusion in this
retrospective observational cohort study. Further inclusion criteria consisted of the presence of dominant esophageal symptoms
(heartburn, regurgitation, and chest pain),18 ambulatory MII-pH
studies performed off acid-suppressive therapy (at least 7 days pharmacological wash-out),19 and 10 acceptable supine water swallows
for HRM analysis using Chicago classification version 3.0 (CC
v3.0).20 Patients with inadequate studies (equipment malfunction,
poor study quality, and artifacts) and/or incomplete HRM studies
were excluded. Patients with achalasia spectrum disorders (integrated relaxation pressure > 15 mmHg), connective tissue disease,
history of neoplasia and prior foregut surgery were also excluded.
The study protocol was approved by the Institutional Review Board
of the 3 University Centers (IRB No. 201607083), and each collaborating institution completed data sharing agreements for analysis of deidentified demographic, clinical, MII-pH and HRM data.
Written informed consent was obtained from all patients.
While esophageal symptoms were required for study inclusion,
the presence of extra-esophageal symptoms (chronic cough, asthma,
hoarseness, and globus) was also recorded. Symptom frequency
(based on number of symptom episodes/week) of esophageal symptoms was assessed before and after at least 8 weeks of standard dose
PPI therapy (Esomeprazole 40 mg once daily [od], Pantoprazole
40 mg od, Lansoprazole 30 mg od, and Omeprazole 20 mg od)
within the previous year on validated institutional self-report Likert
scales on patient questionnaires at each study site.21-24 Patients were
categorized as non-responders if symptom improvement while on
therapy, using these scales, was < 50% compared to symptom assessment off therapy.25

Esophageal High-resolution Manometry
A catheter with 36 circumferential solid state pressure sensors,
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located at 1-cm intervals (Medtronic, Minneapolis, MN, USA)
was inserted, after an overnight fast, through an anesthetized nostril
such that at least 3 distal pressure sensors positioned in the stomach.
The manometric study was performed using ten 5 mL swallows of
ambient temperature fluid at 30-second intervals in a semi-recumbent position.26
Each HRM study was evaluated using the following CC
v3.0 criteria20: (1) intact swallow: distal contractile integral (DCI)
> 450 mmHg∙cm∙sec; (2) fragmented swallow: DCI > 450
mmHg∙cm∙sec with > 5 cm breaks; (3) weak swallow: DCI
100-450 mmHg∙cm∙sec; AND (4) failed swallow: DCI < 100
mmHg∙cm∙sec. CC v3.0 diagnoses consisted of the following: (1)
fragmented peristalsis: ≥ 50% fragmented swallows; (2) ineffective
esophageal motility (IEM): ≥ 50% of any combination of weak or
failed swallows; and (3) absent contractility: 100% failed swallows.
EGJ barrier function and morphology were recorded. EGJ-CI was
evaluated by recording the EGJ barrier vigor (using a DCI like
tool) during a period of quiet rest over exactly 3 respiratory cycles,
and divided by the duration of the respiratory cycles to make the
metric independent of respiration. EGJ-CI was considered low
when < 39.1 mmHg∙cm.8,9
EGJ morphology was determined by the relationship between
lower esophageal sphincter (LES) and crural diaphragm; type I
when LES and crural diaphragm were superimposed, type II when
separated < 3 cm, and type III when separated ≥ 3 cm.7

24-Hour Multichannel Intraluminal Impedance pH
Monitoring
MII-pH was recorded using a 2.3 mm diameter polyvinyl
catheter assembly containing a series of impedance electrodes, each
4 mm in axial length, spaced at 2-cm intervals, and a distal antimony pH electrode (Sandhill Scientific Inc, Highlands Ranch, CO,
USA). The pH electrodes were calibrated using pH 4.0 and pH
7.0 buffer solutions before pH-impedance monitoring. Following
HRM, the MII-pH assembly was passed through the anesthetized
nostril, and positioned with the pH electrode 5 cm above the LES,
and impedance electrodes at 3, 5, 7, 9, 15, and 17 cm proximal to
the LES. Event markers, corroborated with paper diaries, were
used to record symptoms, meal times, and supine periods. AET
was defined as pathological if the time pH < 4 exceeded 6% of the
total recording time,19,27 and non-pathologic if < 6%. Reflux-symptom association was assessed using symptom association probability
(SAP) for all reflux episodes using previously described methodology.28 Mean nocturnal baseline impedance (MNBI) was calculated
by measuring baseline impedance values at 3 cm and 5 cm above

LES, across stable nocturnal 10-minute periods (at or around 1, 2,
and 3 AM). The values from the 3 time periods for both levels were
averaged to yield the mean nocturnal baseline impedance (MNBI)
for each channel. Values < 2292 Ω defined abnormal studies. 29

Gastroesophageal Reflux Disease Phenotypes
Endoscopy negative patients with abnormal AET were defined
as having non-erosive reflux disease (NERD).30 In the context of
esophageal symptoms, patients with normal AET but positive SAP
were diagnosed as reflux hypersensitivity (RH), and those with normal AET and negative SAP were classified as functional heartburn
(FH).27,30

Statistical Methods
Data are presented as mean ± standard deviation. Comparisons between groups were assessed using the Fisher’s exact test.
Group means were compared using ANOVA with Bonferroni
correction. Odds ratios (ORs) with 95% confidence intervals (CI)
were calculated to assess the association between AET, MNBI at
3 cm and 5 cm above the LES, EGJ-CI, EGJ morphology, and
the PPI response. Multivariate regression models were generated
to evaluate if HRM and 24-hour MII-pH parameters were independent predictors for PPI response or non-response. Significance
was achieved when the P -value was < 0.05. Statistical analysis was
performed using SPSS version 16.0 software (SPSS Inc, Chicago,
IL, USA).

Results
Study Population
A total of 204 patients with esophageal symptoms fulfilled inclusion criteria and formed the study cohort (Table 1). Among the
included patients, 105 (54%) non-responders to prior PPI therapy
while 99 (46%) were responders; these did not differ in terms of
sex, age, and body mass index. Extra-esophageal symptoms were
reported by approximately a third of both non-responders and responders, with similar proportions of chronic cough (24% vs 30%,
respectively), asthma (6% vs 4%), hoarseness (10% vs. 11%), and
globus (6% vs 5%, P > 0.05 for each comparison). A total of 21
patients had erosive reflux disease (ERD) (15 grade A, 5 grade B,
and 1 grade C according to Los Angeles classification). Proportions
of ERD patients and endoscopically identified hiatus hernia were
also similar (Table 1).
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Table 1. Demographic and Clinical Characteristics in Non-respond-

70

ers and Responders

Non responders
Responders

60

Responders
(n = 99)

P -value

Male/female
Age (yr)
BMI (kg/m2)
Presence of atypical
symptoms
Erosive esophagitis
Hiatal hernia

46/59
50 (21.1)
23.1 (1.9)
36 (34%)

43/56
47 (18.3)
22.4 (2.1)
29 (29%)

0.891
0.807
0.774
0.452

10 (9%)
19 (18%)

11 (11%)
16 (16%)

0.816
0.847

30

P < 0.01

20
10
0
EGJ type II

EGJ type III

Figure. Proportion of responders and non-responders in patients

Table 2. Esophageal Physiologic Test Results in Responders and

Non-responders

MII-pH
AET (%)
Upright AET (%)
Supine AET (%)
Reflux episodes
MNBI 3 cm (Ω)
MNBI 5 cm (Ω)
HRM
Basal LES pressure (mmHg)
EGJ-CI (mmHg∙cm)
IRP (mmHg)
DCI (mmHg∙cm∙sec)
Absent peristalsis
DES
Fragmented peristalsis
IEM
Normal peristalsis

P < 0.01

40

EGJ type I

BMI, body mass index.
Data are presented as number, mean (SD), or number (%).

Esophageal physiologic
test variables

50

%

Demographic/
Non-responders
clinical characteristics
(n = 105)

Non-responders Responders
P -value
(n = 105)
(n = 99)

with Type I, II, and III esophagogastric junction (EGJ). There were
statistically more non-responders among patients with Type 1 EGJ. In
contrast, with EGJ disruption, the likelihood of response was statistically higher, indirectly indicating that the presence of EGJ disruption
was a marker for abnormal reflux burden.
Table 3. Multivariate Logistic Regression Analysis of Predictors of

4.2 (1.3)
6.2 (2.1)
2.1 (0.9)
51 (17)
2108 (412)
2057 (436)
23.7 (3.3)

7.8 (2.4)
6.7 (2.3)
9.0 (3.4)
64 (23)
1607 (235)
1654 (258)
20.4 (2.8)

0.034
0.225
0.003
0.344
0.027
0.024
0.033

30 (4.2)
8.2 (1.5)
1641 (158)
7 (7%)
1 (1%)
10 (9%)
11 (10%)
76 (73%)

22 (2.1)
7.7 (1.2)
1236 (116)
8 (8%)
0 (0.%)
5 (5%)
15 (15%)
71 (72%)

0.011
0.448
0.029
0.789
0.884
0.278
0.402
0.896

MII-pH, multichannel intraluminal impedance pH; AET, acid exposure time; MNBI, mean nocturnal baseline impedance; HRM, highresolution manometry; LES, lower esophageal sphincter; EGJ-CI,
esophagogastric junction contractile integral; IRP, integrated relaxation pressure; DCI, distal contractile integral; DES, distal esophageal spasm; IEM, ineffective esophageal motility.
Data are presented as mean (SD) or number (%).

Multichannel Intraluminal Impedance pH Data in
Non-responders and Responders
Esophageal acid burden, as measured by AET and MNBI,
was lower in non-responders (Table 2). Non-responders demonstrated significantly lower mean total and supine AET compared to
450

P < 0.01

Proton Pump Inhibitors Non-response
Predictors of PPIs non-response
AET < 6%
Number of reflux episodes
MNBI 3 cm > 2292 Ω
MNBI 5 cm > 2292 Ω
EGJ-CI > 39.1 mmHg∙cm
Type I EGJ
IEM
Fragmented peristalsis
Absent peristalsis

OR (95% CI)

P -value

2.5 (1.2-5.0)

0.011

1.3 (0.6-2.9)
2.7 (1.0-6.1)
2.4 (1.0-5.6)
3 (1.3-7.1)
1.8 (1.0-3.4)
1.8 (0.7-5.2)
0.5 (0.2-1.6)
0.7 (0.4-2.7)

0.608
0.047
0.046
0.012
0.047
0.225
0.324
0.778

PPIs, proton pump inhibitors; AET, acid exposure time; MNBI,
mean nocturnal baseline impedance; EGJ-CI, esophagogastric junction contractile integral; IEM, ineffective esophageal motility.

responders (P ≤ 0.03 for each comparison), despite similar mean
upright AET values (P = 0.229). MNBI values at both the 3 cm
and 5 cm locations were significantly higher in non-responders (P
≤ 0.03 for each comparison). Non-responders and responders reported similar numbers of reflux episodes (P = 0.347).

High-resolution Manometry Data in Non-responders
and Responders
Non-responders demonstrated significantly higher mean basal
LES pressure and EGJ-CI values compared to responders (P ≤
0.03 for each comparison), while mean integrated relaxation pressure values were comparable between the 2 groups (P = 0.438).
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Table 4. High-resolution Manometry Findings in ERD, NERD, RH and FH patients

HRM findings
Basal LES pressure (mmHg)
EGJ-CI (mmHg∙cm)
IRP (mmHg)
DCI (mmHg∙cm∙sec)
Absent peristalsis
DES
Fragmented peristalsis
IEM
Normal peristalsis

ERD (n = 21)
a

20.8 (2.4)
17.5 (4.9)a
6.8 (1.2)
1246 (123)a
4 (19%)b
0 (0%)
2 (10%)b
4 (19%)a
30 (55%)

NERD (n = 50)
a

20.9 (2.5)
21.0 (4.5)a
7.1 (1.1)
1123 (128)a
6 (12%)b
0 (0%)
9 (18%)b
9 (18%)a
26 (52%)

RH (n = 56)

FH (n = 77)

28.6 (3.2)
30.6 (5.9)
8.2 (1.5)
1769 (158)
4 (7%)
1 (2%)
3 (5%)
8 (15%)a
38 (71%)

29.4 (2.8)
32.4 (6.6)
9.1 (1.9)
1989 (201)
1 (1%)
0 (0%)
1 (1%)
3 (4%)
72 (94%)

a

P < 0.05 vs functional heartburn (FH).
P < 0.01 vs FH.
HRM, high-resolution manometry; ERD, erosive reflux disease; NERD, non-erosive reflux disease; RH, reflux hypersensitivity; LES, lower
esophageal sphincter; EGJ-CI, esophagogastric junction contractile integral; IRP, integrated relaxation pressure; DCI, distal contractile integral;
DES, distal esophageal spasm; IEM, ineffective esophageal motility.
Data are presented as mean (SD) or number (%).
b

Mean DCI values were significantly higher in non-responders
compared to responder patients (P = 0.029). Proportions of
patients with absent peristalsis, distal esophageal spasm (DES),
fragmented peristalsis and IEM were comparable between nonresponders and responders (P ≥ 0.3 for each comparison) (Table 2).
There was a significantly lower frequency of type II and III
EGJ morphology in non-responders compared to responders (31%
and 36% vs 17% and 21%, respectively; P < 0.01) (Figure).
On univariate analysis, non-pathologic AET (OR [95% CI],
3 [1.5-5.9]; P = 0.001), normal MNBI values at both the 3 cm
and 5 cm locations (OR [95% CI], 1.9 [1.1-3.1]; P = 0.041 and
1.8 [1.1-2.9]; P = 0.043), normal EGJ-CI values (OR [95%
CI]: 3.4 [1.4-8.0]; P = 0.006), and type I EGJ morphology were
independent predictors of non-response to PPI (OR [95% CI],
1.9 [1.0-3.4], P = 0.046). In contrast, presence of type II and III
EGJ was associated with a significantly higher probability of PPI
response (OR [95% CI], 2 [1.4-2.7]; P < 0.01).
On multivariate analysis, non-pathologic AET, normal MNBI
values at both 3 cm and 5 cm above the LES, normal EGJ-CI values and presence of type I EGJ morphology were associated with
non-response to PPIs (Table 3). On the other hand, pathologic
AET, abnormal MNBI at both 3 cm and 5 cm above the LES,
abnormally low EGJ-CI values and presence of type II-III EGJ
morphology were associated with PPI response (Table 3).

Gastroesophageal Reflux Disease Phenotypes
Among the 183 endoscopy-negative patients, 50 (27%) were
phenotyped as NERD according to MII-pH findings. Fifty-six

(31%) had RH, and the remaining 77 patients (42%), with normal
AET and negative SAP, were characterized as FH. Sixteen patients
out of the 105 non-responders (15%) and 34 patients out of the 99
responders (34%) fulfilled criteria for NERD (P = 0.002).
Mean basal LES pressure, EGJ-CI and DCI values were
significantly lower in ERD and NERD compared to FH and in
RH patients, but other HRM parameters did not differ among the
3 groups. In the NERD and ERD group, a significantly higher
proportion of patients had evidence of esophageal body hypomotility features (absent peristalsis, fragmented peristalsis, and IEM)
compared to FH (P ≤ 0.003 for each comparison, Table 4).

Discussion
In this observational, international multicenter study, we demonstrate that esophageal HRM is more likely to show intact EGJ
metrics in non-responders to acid suppressive therapy, suggesting
that the generation of esophageal symptoms occur without evidence
of abnormal GERD pathophysiology at the EGJ. In contrast,
abnormal EGJ morphology and barrier function were strongly
associated with PPI response, indicating that these features are
primary HRM markers of abnormal reflux burden in the esophagus. Indeed, similar EGJ disruption is demonstrated in patients
with characteristics of NERD, in contrast to FH. We conclude
that evaluation of esophageal motor function, and interpretation of
HRM using CC v3.0 as well as novel EGJ metrics is useful in the
investigation of PPI non-responders.
We made efforts to select a large group of patients with
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esophageal symptoms across multiple centers in order to evaluate a
representative patient cohort, with meticulous characterization into
responders and non-responders based on patient questionnaires
and therapeutic outcome evaluation. Indeed, our designation into
responder status appears appropriate, since responders had higher
AET as well as lower MNBI, both features that have been documented to predict treatment response.31-33 While it is conceivable
that non-responders may have had higher proportions of weakly
acid reflux episodes, the overall proportions of reflux episodes were
similar between responders and non-responders (Table 2). Therefore, it is more likely that non-responders may have non-reflux
mechanisms of symptom generation.34
Our findings demonstrate that PPI non-responders have a
higher likelihood of having intact EGJ barrier function, and intact
esophageal body contraction vigor, compared to responders. We
demonstrate a higher likelihood of PPI response in the presence of a
hiatus hernia (EGJ morphology types II and III), which is a known
marker for abnormal esophageal reflux burden compared to normal
EGJ morphology (type I EGJ, no hiatus hernia).8 Our findings
therefore concur with data that demonstrate that abnormal esophageal acid burden predicts PPI response.35 Further, our MNBI data
also supports the fact that abnormal values of MNBI at 3 cm and 5
cm above the LES are characterized by a favorable response to acid-suppressive therapy.33 The EGJ-CI is a novel HRM tool that is
gaining acceptance as a metric for assessment of EGJ barrier function. This has been demonstrated to be associated with abnormal
reflux burden, especially when esophageal body evaluation shows
IEM, since IEM is another HRM metric that predicts abnormal
reflux burden.36 Supporting these conclusions, non-responders in
our study demonstrate higher basal LES pressure, EGJ-CI, and
DCI mean values, as well as lower total and supine mean AET
values. Consistent with previous reports, the manometric finding of
a hiatus hernia (EGJ morphology types II and III, 44% of patients)
was higher than the endoscopic recording of a hiatus hernia (17% of
patients, P < 0.01). It is now well recognized that HRM is more
accurate than endoscopy in the identification of a hiatus hernia,37,38
which adds to the value of HRM in the context of GERD, particularly since our data and other reports demonstrate that a manometric hiatus hernia is predictive of abnormal reflux burden,36,39 and
our current findings show a higher proportion of PPI responders
with a manometric hiatus hernia.
While EGJ disruption or dysfunction is a primary pathophysiologic factor in determining reflux occurrence, esophageal body
motor function influences duration of contact of the refluxate with
the esophageal mucosa. Consequently, impaired esophageal peri452

stalsis may account for delayed bolus transit and reduced esophageal reflux clearance in patients with GERD.9 Large breaks are
often identified in the context of suspected GERD-related chronic
cough,16,17 the presence of which can be associated with suboptimal
benefit from antireflux therapy.16 Finally, failed swallows, which
represent panesophageal breaks in peristaltic integrity, predict abnormal AET better than ineffective swallows without long breaks in
peristaltic integrity.10 In this study, we did not identify any of these
esophageal body motor findings as predictors of PPI non-response.
Our results also show that mean basal LES pressure and EGJCI values were significantly lower in ERD and NERD patients
compared to FH and in RH patients. Moreover, a significantly
higher proportion of esophageal body hypomotility (fragmented
peristalsis, IEM, and absent contractility) was also observed in
these cohorts compared to FH. This supports the argument
that the modern definition of NERD, which requires abnormal
esophageal reflux burden in addition to absence of erosive disease,
demonstrates abnormal EGJ and esophageal body motor characteristics that have been shown to be associated with abnormal reflux
burden. This is consistent with existing evidence that suggests that
PPI non-response may be a marker for non-GERD mechanisms
of symptom generation,34 wherein motor features associated with
GERD pathophysiology are identified less often, and MII-pH
demonstrates features of FH. Our findings support the classification of motor findings proposed by the GERD consensus group,
where hierarchical reporting of EGJ and esophageal body motor
features is recommended in HRM studies performed in the context
of GERD.7
To our knowledge, this is the first study evaluating the role of
the HRM parameters and their association with PPI response in
a large series of responders and non-responders. Strengths of the
present study are the number of patients included and rigorous
selection process. However, some limitations temper the strength
of our findings, the predominant limitation relating to retrospective patient identification and data analysis for the purpose of this
multicenter study, despite the fact that data collection was prospectively performed independent of the current study across the
3 sites. Questionnaire data can be subject to recall bias. Patients
were evaluated after at least 8-week PPI treatment, however some
patients have been evaluated after a longer period of standard dose
PPI therapy. Additional psychological and psychosocial factors
influencing symptom presentation and PPI non-response, as well
as alternate medications (such as neuromodulators) contributing
to symptom response were not addressed. Moreover, it is well established that multiple factors contribute to non-response, and our
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designation of non-response could have been biased by patient related factors that were not evaluated in this study. Finally, we could
not address further outcome following the performance of these
esophageal tests and due to the retrospective nature of the study.
Nevertheless, despite these limitations, our results demonstrate the
value of assessing esophageal motor function in patients with persisting esophageal symptoms, and identify a clear role for HRM in
these clinical settings.
In summary, our results demonstrate that impaired esophageal
function on HRM associates with increased reflux burden, and
consequently, a better response to PPI therapy. On the other hand,
patients not responding to acid suppressive therapy are characterized by a less severe reflux burden and better HRM metrics, implying a non-GERD mechanism for symptom persistence. These
results lead to the conclusion that HRM should be performed and
taken into account before subjecting patients with symptoms suggestive of GERD to anti-reflux therapies, and that the future iteration of the CC should incorporate this information in the context of
assessment of patients with GERD.
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